Clinical Trial Update: AZD9291 First Time In Patients Ascending Dose Study [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 ascending-dose study of AZD9291 (osimertinib) in advanced non-small cell lung cancer completed; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-10-06